



December 4, 2012

## **Astex Pharmaceuticals Announces December 14th Analyst and Investor Day Agenda**

DUBLIN, Calif., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the agenda for its Analyst and Investor Day webcast, to take place from 10 am to 12:15 pm GMT on Friday, December 14th in London, UK.

Investors and interested parties may access the webcast in the Investor Events section of the Company's website, [www.astx.com](http://www.astx.com). A webcast replay will be available for 90 days following the live event.

10:00 (5 min.)	Welcome and Introductions	Timothy L. Enns SVP, Corporate Communications and Marketing
10:05 (10 min.)	Corporate Overview	James S.J. Manuso, PhD, MBA Chairman and Chief Executive Officer
10:15 (20 min.)	Clinical Update	Mohammad Azab, MD, M Sc, MBA Chief Medical Officer
10:35 (25 min.)	AT13387 & Prostate Cancer	Johann de Bono, MD, PhD Royal Marsden Hospital Institute of Cancer Research (ICR)
11:00 (25 min.)	SGI-110 & Ovarian Cancer	Robert Brown, PhD Imperial College London Institute of Cancer Research (ICR)
11:25 (20 min.)	Research & Discovery	Harren Jhoti, PhD President and Director
11:45 (15 min.)	Partnering & Corporate Development	Martin Buckland, DPhil, MBA Chief Business Officer
12:00 (10 min.)	Financial Overview	Michael Molquentin, CPA Chief Financial Officer and Corporate Secretary
12:10 (5 min.)	Closing Remarks	James S.J. Manuso, PhD, MBA Chairman and Chief Executive Officer

The times listed above are approximate and are subject to change.

### **About Astex Pharmaceuticals**

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for

partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit <http://www.astx.com>.

The Astex Pharmaceuticals, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=12273>

CONTACT: Timothy L. Enns

Astex Pharmaceuticals, Inc.

Senior Vice President

Corporate Communications & Marketing

Tel: +1 (925) 560-2810

E-mail: [tim.enns@astx.com](mailto:tim.enns@astx.com)

Susanna Chau

Astex Pharmaceuticals, Inc.

Manager

Investor Relations

Tel: +1 (925) 560-2845

E-mail: [susanna.chau@astx.com](mailto:susanna.chau@astx.com)

Alan Roemer

The Trout Group

Managing Director

Tel: +1 (646) 378-2945

E-mail: [aroemer@troutgroup.com](mailto:aroemer@troutgroup.com)

Kari Watson

MacDougall Biomedical Communications

Senior Vice President

Tel: +1 (781) 235-3060

E-mail: [kwatson@macbiocom.com](mailto:kwatson@macbiocom.com)